IL34 and lymphoma: DLBCL is the most common subtype of non‐Hodgkin lymphoma and curable even in advanced stages, but up to one‐third of patients will not achieve cure with initial therapy.20, 21, 22, 23 Moreover, we show that the IL‐34 expression correlates with a poor prognosis of DLBCL patients and the number of macrophages in the lymphoma tissues.